## Rasmus Sejersten Ripa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8155488/publications.pdf

Version: 2024-02-01

77 papers

2,018 citations

331538 21 h-index 254106 43 g-index

79 all docs

79 docs citations

times ranked

79

2584 citing authors

#	Article	IF	CITATIONS
1	Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction. Circulation, 2006, 113, 1983-1992.	1.6	331
2	Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. European Heart Journal, 2006, 27, 1785-1792.	1.0	136
3	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2008, 51, 1429-1437.	1.2	136
4	<sup>64</sup> Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1696-1703.	1.1	108
5	Bone Marrow–Derived Mesenchymal Cell Mobilization by Granulocyte-Colony Stimulating Factor After Acute Myocardial Infarction. Circulation, 2007, 116, I24-30.	1.6	101
6	YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scandinavian Cardiovascular Journal, 2008, 42, 295-302.	0.4	93
7	Short- and long-term changes in myocardial function, morphology, edema, and infarct mass after ST-segment elevation myocardial infarction evaluated by serial magnetic resonance imaging. American Heart Journal, 2007, 154, 929-936.	1.2	70
8	Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scandinavian Cardiovascular Journal, 2011, 45, 161-168.	0.4	69
9	<sup>64</sup> Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with <sup>68</sup> Ga-DOTATOC in 60 Patients. Journal of Nuclear Medicine, 2015, 56, 1895-1900.	2.8	67
10	Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 361-71.	1.0	53
11	The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflammation Research, 2011, 60, 281-287.	1.6	46
12	18F-FDG PET Imaging of Murine Atherosclerosis: Association with Gene Expression of Key Molecular Markers. PLoS ONE, 2012, 7, e50908.	1.1	40
13	In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor. International Journal of Cardiology, 2006, 111, 174-177.	0.8	38
14	Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. European Heart Journal, 2008, 29, 1819-1826.	1.0	38
15	Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy?. European Heart Journal, 2006, 27, 2748-2754.	1.0	37
16	Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 80-86.	0.6	31
17	Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study. PLoS ONE, 2013, 8, e72066.	1.1	30
18	Timing of ischemic onset estimated from the electrocardiogram is better than historical timing for predicting outcome after reperfusion therapy for acute anterior myocardial infarction: A DANish trial in Acute Myocardial Infarction 2 (DANAMI-2) substudy. American Heart Journal, 2007, 154, 61.e1-61.e8.	1.2	28

#	Article	IF	CITATIONS
19	Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction—A magnetic resonance study. Molecular Immunology, 2013, 54, 408-414.	1.0	27
20	Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovascular Research, 2019, 115, 1519-1532.	1.8	25
21	HIV infection and arterial inflammation assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET): A prospective cross-sectional study. Journal of Nuclear Cardiology, 2015, 22, 372-380.	1.4	24
22	Comparison of infarct size changes with delayed contrast-enhanced magnetic resonance imaging and electrocardiogram QRS scoring during the 6 months after acutely reperfused myocardial infarction. Journal of Electrocardiology, 2008, 41, 609-613.	0.4	21
23	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	1.6	21
24	G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction—A relevant treatment?. Experimental Hematology, 2008, 36, 681-686.	0.2	20
25	Comparison between human and automated electrocardiographic waveform measurements for calculating the Anderson-Wilkins acuteness score in patients with acute myocardial infarction. Journal of Electrocardiology, 2005, 38, 96-99.	0.4	19
26	Usefulness of Quantitative Baseline ST-Segment Elevation for Predicting Outcomes After Primary Coronary Angioplasty or Fibrinolysis (Results from the DANAMI-2 Trial). American Journal of Cardiology, 2006, 97, 611-616.	0.7	19
27	Serial in vivo imaging of the porcine heart after percutaneous, intramyocardially injected 111In-labeled human mesenchymal stromal cells. International Journal of Cardiovascular Imaging, 2010, 26, 273-284.	0.7	19
28	Effect of Liraglutide on Arterial Inflammation Assessed as [ <sup>18</sup> F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	1.3	18
29	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology, 2021, 12, 790405.	1.5	16
30	Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy. Medicine (United States), 2015, 94, e1886.	0.4	15
31	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology, 2020, 27, 1698-1707.	1.4	15
32	Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease â€" Indicators of myocardial ischemic burden?. International Journal of Cardiology, 2007, 120, 181-187.	0.8	14
33	Imaging Atherosclerosis with Hybrid Positron Emission Tomography/Magnetic Resonance Imaging. BioMed Research International, 2015, 2015, 1-8.	0.9	14
34	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e002395.	1.2	14
35	Timing of granulocyte-colony stimulating factor treatment after acute myocardial infarction and recovery of left ventricular function: Results from the STEMMI trial. International Journal of Cardiology, 2010, 140, 351-355.	0.8	13
36	Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis, 2022, 352, 88-95.	0.4	13

#	Article	IF	CITATIONS
37	<sup>123</sup> lâ€ <scp>MIBG</scp> imaging for detection of anthracyclineâ€induced cardiomyopathy. Clinical Physiology and Functional Imaging, 2018, 38, 176-185.	0.5	12
38	Retention and Functional Effect of Adipose-Derived Stromal Cells Administered in Alginate Hydrogel in a Rat Model of Acute Myocardial Infarction. Stem Cells International, 2018, 2018, 1-13.	1.2	12
39	18F-FDG PET/MR-imaging in a Göttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression. Atherosclerosis, 2019, 285, 55-63.	0.4	12
40	Rubidium-82 PET imaging is feasible in a rat myocardial infarction model. Journal of Nuclear Cardiology, 2019, 26, 798-809.	1.4	12
41	Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 448-58.	1.0	12
42	Positron emission tomography of the vulnerable atherosclerotic plaque in man – a contemporary review. Clinical Physiology and Functional Imaging, 2014, 34, 413-425.	0.5	11
43	The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 722-728.	0.6	10
44	Microbiota-Dependent Marker TMAO is Not Associated With Decreased Myocardial Perfusion in Well-Treated HIV-Infected Patients as Assessed by 82Rubidium PET/CT. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e83-e85.	0.9	10
45	Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G. Open Forum Infectious Diseases, 2018, 5, ofy205.	0.4	10
46	Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Daysâ∈™ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial. Cardiology, 2005, 5, 177-182.	0.3	9
47	Non-Invasive Imaging for Subclinical Coronary Atherosclerosis in Patients with Peripheral Artery Disease. Current Atherosclerosis Reports, 2014, 16, 415.	2.0	9
48	Clinical outcome after stem cell mobilization with granulocyte-colony-stimulating factor after acute ST-elevation myocardial infarction: 5-year results of the STEMMI trial. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 125-129.	0.6	7
49	Perfusion imaging using rubidium-82 (82Rb) PET in rats with myocardial infarction: First small animal cardiac 82Rb-PET. Journal of Nuclear Cardiology, 2017, 24, 750-752.	1.4	7
50	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
51	Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease. Danish Medical Journal, 2012, 59, B4411.	0.5	7
52	Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 570, 89-96.	0.4	6
53	REGENT trial—the end of cell therapy for MI?. Nature Reviews Cardiology, 2009, 6, 567-568.	6.1	6
54	Instent neointimal hyperplasia after percutaneous intervention for ST-elevation myocardial infarction and treatment with granulocyte-colony stimulating factor. Results from the stem cells in myocardial infarction (STEMMI) trial. International Journal of Cardiology, 2010, 139, 269-275.	0.8	6

#	Article	IF	Citations
55	PET/MR Imaging in Vascular Disease. PET Clinics, 2016, 11, 479-488.	1.5	6
56	Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients. Diagnostics, 2017, 7, 31.	1.3	6
57	Subacute cardiac rubidium-82 positron emission tomography (82Rb-PET) to assess myocardial area at risk, final infarct size, and myocardial salvage after STEMI. Journal of Nuclear Cardiology, 2018, 25, 970-981.	1.4	6
58	Epo 'cytokine-doping' of heart disease patients, will it work?. European Heart Journal, 2006, 27, 1767-1768.	1.0	5
59	123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. Journal of Nuclear Cardiology, 2020, 27, 931-939.	1.4	5
60	Myocardial perfusion recovery induced by an $\hat{l}\pm$ -calcitonin gene-related peptide analogue. Journal of Nuclear Cardiology, 2022, 29, 2090-2099.	1.4	5
61	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
62	The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 11758.	1.8	5
63	Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease. Scandinavian Cardiovascular Journal, 2007, 41, 397-404.	0.4	4
64	Small animal positron emission tomography imaging and <i>in vivo</i> studies of atherosclerosis. Clinical Physiology and Functional Imaging, 2013, 33, 173-185.	0.5	4
65	Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients. Journal of Nuclear Cardiology, 2019, 26, 471-482.	1.4	4
66	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. Diabetic Medicine, 2021, 38, e14517.	1.2	4
67	Amiodarone attenuates cardiac Rubidium-82 in consecutive PET/CT scans in a rodent model. Journal of Nuclear Cardiology, 2022, 29, 2853-2862.	1.4	4
68	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. Frontiers in Endocrinology, 2021, 12, 780679.	1.5	4
69	(18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivors. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 408-15.	1.0	3
70	In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET). Atherosclerosis, 2022, 352, 103-111.	0.4	2
71	Flow Cytometric Evaluation of the Ongoing Angiogenic Response in Rat Cardiac Tissue Following Myocardial Infarction. Current Protocols, 2021, 1, e40.	1.3	1
72	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1638-1642.	2.2	1

#	Article	IF	CITATIONS
73	Symptomatic Carotid Plaques Show Decreased (18)F-Fluorodeoxyglucose (FDG) Uptake on Positron Emission Tomography (PET) After 3 Months Follow-up from Last Symptom. European Journal of Vascular and Endovascular Surgery, 2019, 58, e621-e622.	0.8	O
74	Carotid plaque inflammatory activity assessed by 2-[18F]FDG-PET imaging decrease after a neurological thromboembolic event. EJNMMI Research, 2021, $11$ , $30$ .	1.1	0
75	Abstract 460: <sup>64</sup> Cu-DOTATATE for in vivo Positron Emission Tomography Imaging of Somatostatin Receptor 2 Expressing Macrophages in a Göttingen Minipig Model of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	O
76	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Frontiers in Clinical Diabetes and Healthcare, 2022, 3, .	0.3	0
77	Editorial: Advanced Cardiovascular Imaging in Diabetes. Frontiers in Endocrinology, 2022, 13, 848975.	1.5	0